Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Broad USD Investment Grade Corporate Bond (USIG) vs GeneDx Holdings Corp (WGS) Price & Performance

iShares Broad USD Investment Grade Corporate BondTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

iShares Broad USD Investment Grade Corporate Bond vs GeneDx Holdings Corp — how do they compare? iShares Broad USD Investment Grade Corporate Bond trades at $50.26, while GeneDx Holdings Corp trades at $82.41 (market cap $2.44B). The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.

USIGWGS
Sector
Fixed IncomeTechnology
52-Week High
$52.69$167.51
52-Week Low
$50.18$34.51
Market Cap
$2.44B
Enterprise Value
$2.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Broad USD Investment Grade Corporate Bond

USIG trades at $50.26, up 0.16% on the day, with a bearish technical signal from moving averages. Recent corporate actions include dividend payments, with the latest being $0.21 per share. The company's subsidiaries maintained credit ratings following a transaction with Tiptree Inc., as noted by AM Best on July 30, 2026.

The outlook is mixed, with technical indicators signaling caution, but institutional interest is present, as Bank of New York Mellon Corp increased its stake. Key risks include market volatility and execution of corporate strategies. The stock presents opportunities for income-focused investors due to dividends, but requires monitoring of fundamental developments.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.

Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.

Returns comparison

Trailing returns across standard periods

About iShares Broad USD Investment Grade Corporate Bond

USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.

Read more on USIG

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS